EARLY FDG‐PET ADAPTED TREATMENT OF LIMITED STAGE HODGKIN LYMPHOMA (HL): 10Y LONG TERM FOLLOW‐UP ANALYSIS OF THE RANDOMIZED INTERGROUP EORTC/LYSA/FIL H10 TRIAL

Background: Though the outcome of patients with stage I/II HL is excellent standard combined chemo- and radiotherapy, H10 trial assessed possibility improving tumor control by treatment intensification in early (i.e., after two cycles ABVD) PET-positive reducing related toxicity omission involved-node radiotherapy (INRT) PET-negative patients. Here, we present results 10y long term follow-up analysis, focused on progression-free survival (PFS), overall (OS). Methods: was a randomized to evaluate adaptation basis PET (ePET) ABVD previously untreated I II HL—according European Organisation for Research Treatment Cancer criteria favorable (F) unfavorable (U). The arm consisted followed (INRT), regardless ePET result. In experimental arm, ePET-negative received only (noninferiority design), whereas ePET-positive switched BEACOPPesc INRT (superiority design). Primary end point (PFS). January 2019, preplanned analysis launched. So far, out 1925 constituting original study population, 1419 cases have been updated, are included analysis; 506 showing similar baseline characteristics 5y OS PFS than updated were excluded so far. Results: After median 9.5 yrs, total 57 deaths 136 events reported analyzed leading an 10-year rates 96% 90% respectively. patients, increased from 79% + 85% (hazard ratio [HR] = 0.67; 95% CI, 0.37 1.20), although difference not statistically significant. 92%, respectively 0.92; 0.43–1.97). F negative group 99% versus (HR 13.2; 3.1–55.8) favor INRT, 100% 98% arms, 2.80; 0.3–26.9). Finally, U 91% 87% 1.52; 0.8–2.8) 94% 0.84; 0.4–2.0). Conclusion: long-term confirms that associated lower PFS, no differences terms emerged. Moreover, positive significant between arms emerged OS. Keyword: Hodgkin lymphoma No conflicts interests pertinent abstract.